ABSTRACT
Background: The patients with COVID-19 disease are at high risk for thrombosis. More aggressive thromboprophylaxis anticoagulation are considered in these patients. Several reports indicates a higher HIT incidence in the patients with COVID-19 than other medical patients, Aims: We conducted this study to evaluate the frequency of HIT among patients with COVID-19 in comparison with non-COVID- 19 patients. Method(s): The study population included patients who referred to the Iranian blood transfusion organization (IBTO) reference coagulation laboratory for anti-PF4/ H Ab testing (LFIA method, STic EXPERT, STAGO) during a 30 months period before and after the COVID-19 pandemic in Iran. On 19 February 2020, Iran reported its first confirmed cases of infections in Qom. The patients have been divided into three groups: Group1, Sep 2019-Feb 2020 (before COVID-19 pandemic in Iran), group 2: March 2020-Aug 2020 (the first and second peaks), group 3: Sep2020-Feb 2021 (the third and fourth peaks). The demographic data;4Ts score, Anti PF4-Ab (LIFA), and HIPA test results were evaluated. The HIPA test was checked in cases with the positive result of LFIA test. Result(s): A total number of 110 patients have been referred for anti- PF4 Ab testing to our laboratory center during a 30 months period with the detail in table 1and 2. The rate of positive LFIA was 10 % and 33% in the non-Covid- 19 and Covid-19 patients respectively (OR = 4.1%, 95% CI, P-value: 0.022). HIPA test was assessed in 4 cases of Covid-19 and all were positive (definitive HIT). Conclusion(s): Among 110 referral cases in 30 months period who were referred for Anti PF4/H Ab testing to our lab, 94 ( 85%) of cases were referred during the first year of the Covid-19 pandemic in Iran. Regarding the rate of definite HIT (>=16%) among Covid-19 patients, our data confirm the high rate of HIT in this group of patients. (Table Presented).
ABSTRACT
Somatic symptoms are one of the most common complaints among patients with psychiatric disorders and are considered as one of the most common psychiatric disorders in the new coronavirus pandemic. This study aimed to evaluate the effect of the COVID-19 pandemic on the physical symptoms in patients with mood disorders and compare it with healthy individuals. In this case-control study, 67 patients with mood disorders were referred to the psychiatric clinic of 5 Azar Hospital in Gorgan, who met the inclusion criteria, and 68 healthy individuals as control group were entered into the study. For all participants after informed consent, a demographic information questionnaire was completed along with Screening for Somatic Symptoms-7 (SOMS7) and Patient Health Questionnaire-15 (PHQ-15), and the data were analysed by SPSS software version 25. The mean score obtained for the SOMS-7 questionnaire for the group of patients with mood disorders and the control group was 32.37 ± 8.19 and 35.42 ± 11.3, respectively. The mean obtained for the PHQ-15 questionnaire for the mood disorders group and the control group was 8.56 ± 5.93 and 5.86 ± 4.63, respectively. In the mood disorder group, 26.9% of patients had no risk for physical symptoms, 31.3% of patients had a low risk, 25.4% of patients had a moderate risk, and 16.4% of patients had a high risk for physical symptoms. The statistical test showed that although the risk of physical symptoms was high in both groups, this rate was higher in the group with mood disorders, and there is a significant difference between the two groups (P < 0.05). The results also showed a significant and direct relationship between the two questionnaires (P < 0.05). According to the results, although the prevalence of somatic symptoms increased in both groups, the prevalence of somatic symptoms is significantly higher in the mood disorder group.